Acrux begins anti-nausea trial
Wednesday, 02 March, 2005
Acrux (ASX:ACR) has commenced dosing in a Phase I clinical trial utilising its MDTS transdermal spray to deliver anti-nausea drug granisetron. The pharmacokinetics trial will compare absorption of the drug, which is used to treat nausea in chemotherapy patients, against that of an oral formulation in six healthy volunteers.
"Prevention of nausea during chemotherapy with a product that does not require injections or tablets would help minimise distress for cancer patients," said Acrux CEO Igor Gonda. Brisbane-based CRO Q-Pharm is conducting the trial in its clinical trials facilities at the Royal Brisbane Hospital for Acrux subsidiary Acrux DDS.
Stress during pregnancy could affect the baby's development
Maternal stress could leave epigenetic imprints on genes in the placenta associated with...
Bird flu detected at Victorian poultry farm
Agriculture Victoria has confirmed the presence of avian influenza at a poultry property in...
Common mouth and gut bacteria may increase stroke risk
A common bacteria usually found in the mouth and gastrointestinal tract appears to be abundant in...
